ArticleTherapeutic advances in gastroenterology2024

Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: an analysis of the phase II OASIS and phase III ELEVATE UC 52 and ELEVATE UC 12 clinical trials.

Charlie W Lees et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.